nodes	percent_of_prediction	percent_of_DWPC	metapath
Prochlorperazine—HTR2C—Sorafenib—thyroid cancer	0.275	0.475	CbGbCtD
Prochlorperazine—CYP3A4—Vandetanib—thyroid cancer	0.087	0.15	CbGbCtD
Prochlorperazine—CYP2D6—Sorafenib—thyroid cancer	0.0824	0.142	CbGbCtD
Prochlorperazine—CYP3A4—Sorafenib—thyroid cancer	0.0524	0.0906	CbGbCtD
Prochlorperazine—CYP2D6—Doxorubicin—thyroid cancer	0.05	0.0864	CbGbCtD
Prochlorperazine—Keratopathy—Vandetanib—thyroid cancer	0.0457	0.108	CcSEcCtD
Prochlorperazine—Corneal deposits—Vandetanib—thyroid cancer	0.0339	0.0803	CcSEcCtD
Prochlorperazine—CYP3A4—Doxorubicin—thyroid cancer	0.0318	0.055	CbGbCtD
Prochlorperazine—Brain oedema—Vandetanib—thyroid cancer	0.0216	0.0513	CcSEcCtD
Prochlorperazine—Abnormal pigmentation—Epirubicin—thyroid cancer	0.0164	0.0388	CcSEcCtD
Prochlorperazine—Abnormal pigmentation—Doxorubicin—thyroid cancer	0.0151	0.0359	CcSEcCtD
Prochlorperazine—Altered state of consciousness—Vandetanib—thyroid cancer	0.0134	0.0318	CcSEcCtD
Prochlorperazine—Sudden death—Vandetanib—thyroid cancer	0.0121	0.0287	CcSEcCtD
Prochlorperazine—Embolism venous—Sorafenib—thyroid cancer	0.00827	0.0196	CcSEcCtD
Prochlorperazine—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.00574	0.0136	CcSEcCtD
Prochlorperazine—Venous thromboembolism—Epirubicin—thyroid cancer	0.00525	0.0124	CcSEcCtD
Prochlorperazine—Venous thromboembolism—Doxorubicin—thyroid cancer	0.00485	0.0115	CcSEcCtD
Prochlorperazine—Pigmentation disorder—Epirubicin—thyroid cancer	0.00462	0.011	CcSEcCtD
Prochlorperazine—Hypoglycaemia—Vandetanib—thyroid cancer	0.0046	0.0109	CcSEcCtD
Prochlorperazine—Pigmentation disorder—Doxorubicin—thyroid cancer	0.00427	0.0101	CcSEcCtD
Prochlorperazine—Cardiac arrest—Vandetanib—thyroid cancer	0.00427	0.0101	CcSEcCtD
Prochlorperazine—Dysphagia—Vandetanib—thyroid cancer	0.00388	0.00921	CcSEcCtD
Prochlorperazine—Influenza—Vandetanib—thyroid cancer	0.00388	0.00921	CcSEcCtD
Prochlorperazine—Gynaecomastia—Sorafenib—thyroid cancer	0.00373	0.00886	CcSEcCtD
Prochlorperazine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00354	0.0084	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Vandetanib—thyroid cancer	0.0035	0.0083	CcSEcCtD
Prochlorperazine—Eczema—Sorafenib—thyroid cancer	0.00337	0.008	CcSEcCtD
Prochlorperazine—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00321	0.00761	CcSEcCtD
Prochlorperazine—Embolism venous—Epirubicin—thyroid cancer	0.00306	0.00725	CcSEcCtD
Prochlorperazine—Erythema multiforme—Vandetanib—thyroid cancer	0.00294	0.00697	CcSEcCtD
Prochlorperazine—Embolism venous—Doxorubicin—thyroid cancer	0.00283	0.00671	CcSEcCtD
Prochlorperazine—Arrhythmia—Vandetanib—thyroid cancer	0.00277	0.00658	CcSEcCtD
Prochlorperazine—Dysphagia—Sorafenib—thyroid cancer	0.00262	0.00621	CcSEcCtD
Prochlorperazine—Muscle spasms—Vandetanib—thyroid cancer	0.0026	0.00617	CcSEcCtD
Prochlorperazine—Vision blurred—Vandetanib—thyroid cancer	0.00255	0.00605	CcSEcCtD
Prochlorperazine—Tremor—Vandetanib—thyroid cancer	0.00253	0.00601	CcSEcCtD
Prochlorperazine—Eruption—Epirubicin—thyroid cancer	0.00251	0.00595	CcSEcCtD
Prochlorperazine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00241	0.00572	CcSEcCtD
Prochlorperazine—Cough—Vandetanib—thyroid cancer	0.00236	0.0056	CcSEcCtD
Prochlorperazine—Convulsion—Vandetanib—thyroid cancer	0.00234	0.00556	CcSEcCtD
Prochlorperazine—Eruption—Doxorubicin—thyroid cancer	0.00232	0.0055	CcSEcCtD
Prochlorperazine—Jaundice—Sorafenib—thyroid cancer	0.00227	0.0054	CcSEcCtD
Prochlorperazine—Dry mouth—Vandetanib—thyroid cancer	0.00225	0.00534	CcSEcCtD
Prochlorperazine—Oedema—Vandetanib—thyroid cancer	0.00221	0.00524	CcSEcCtD
Prochlorperazine—Infection—Vandetanib—thyroid cancer	0.00219	0.0052	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00216	0.00513	CcSEcCtD
Prochlorperazine—Skin disorder—Vandetanib—thyroid cancer	0.00214	0.00508	CcSEcCtD
Prochlorperazine—Insomnia—Vandetanib—thyroid cancer	0.002	0.00473	CcSEcCtD
Prochlorperazine—Erythema multiforme—Sorafenib—thyroid cancer	0.00198	0.0047	CcSEcCtD
Prochlorperazine—Dyspnoea—Vandetanib—thyroid cancer	0.00197	0.00467	CcSEcCtD
Prochlorperazine—Glycosuria—Epirubicin—thyroid cancer	0.0019	0.00452	CcSEcCtD
Prochlorperazine—Constipation—Vandetanib—thyroid cancer	0.00189	0.00448	CcSEcCtD
Prochlorperazine—Arrhythmia—Sorafenib—thyroid cancer	0.00187	0.00444	CcSEcCtD
Prochlorperazine—Blood disorder—Epirubicin—thyroid cancer	0.00185	0.00438	CcSEcCtD
Prochlorperazine—Liver injury—Epirubicin—thyroid cancer	0.00183	0.00435	CcSEcCtD
Prochlorperazine—Erythema—Sorafenib—thyroid cancer	0.00182	0.00433	CcSEcCtD
Prochlorperazine—Glycosuria—Doxorubicin—thyroid cancer	0.00176	0.00418	CcSEcCtD
Prochlorperazine—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00175	0.00416	CcSEcCtD
Prochlorperazine—Amenorrhoea—Epirubicin—thyroid cancer	0.00175	0.00416	CcSEcCtD
Prochlorperazine—Muscle spasms—Sorafenib—thyroid cancer	0.00175	0.00416	CcSEcCtD
Prochlorperazine—Body temperature increased—Vandetanib—thyroid cancer	0.00174	0.00414	CcSEcCtD
Prochlorperazine—Blood disorder—Doxorubicin—thyroid cancer	0.00171	0.00405	CcSEcCtD
Prochlorperazine—Liver injury—Doxorubicin—thyroid cancer	0.0017	0.00402	CcSEcCtD
Prochlorperazine—Angioedema—Sorafenib—thyroid cancer	0.00167	0.00395	CcSEcCtD
Prochlorperazine—Dyskinesia—Epirubicin—thyroid cancer	0.00164	0.00389	CcSEcCtD
Prochlorperazine—Leukopenia—Sorafenib—thyroid cancer	0.00163	0.00387	CcSEcCtD
Prochlorperazine—Amenorrhoea—Doxorubicin—thyroid cancer	0.00162	0.00385	CcSEcCtD
Prochlorperazine—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00162	0.00385	CcSEcCtD
Prochlorperazine—Cough—Sorafenib—thyroid cancer	0.00159	0.00378	CcSEcCtD
Prochlorperazine—Gait disturbance—Epirubicin—thyroid cancer	0.00158	0.00375	CcSEcCtD
Prochlorperazine—Pruritus—Vandetanib—thyroid cancer	0.00156	0.0037	CcSEcCtD
Prochlorperazine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00154	0.00366	CcSEcCtD
Prochlorperazine—Pulmonary embolism—Epirubicin—thyroid cancer	0.00154	0.00366	CcSEcCtD
Prochlorperazine—Dermatitis contact—Epirubicin—thyroid cancer	0.00152	0.00362	CcSEcCtD
Prochlorperazine—Dry mouth—Sorafenib—thyroid cancer	0.00152	0.0036	CcSEcCtD
Prochlorperazine—Dyskinesia—Doxorubicin—thyroid cancer	0.00152	0.0036	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00149	0.00353	CcSEcCtD
Prochlorperazine—Infection—Sorafenib—thyroid cancer	0.00148	0.00351	CcSEcCtD
Prochlorperazine—Gait disturbance—Doxorubicin—thyroid cancer	0.00146	0.00347	CcSEcCtD
Prochlorperazine—Dizziness—Vandetanib—thyroid cancer	0.00146	0.00346	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00146	0.00346	CcSEcCtD
Prochlorperazine—Aplastic anaemia—Epirubicin—thyroid cancer	0.00145	0.00343	CcSEcCtD
Prochlorperazine—Skin disorder—Sorafenib—thyroid cancer	0.00145	0.00343	CcSEcCtD
Prochlorperazine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00143	0.00338	CcSEcCtD
Prochlorperazine—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00143	0.00338	CcSEcCtD
Prochlorperazine—Dermatitis contact—Doxorubicin—thyroid cancer	0.00141	0.00334	CcSEcCtD
Prochlorperazine—Coma—Epirubicin—thyroid cancer	0.00141	0.00334	CcSEcCtD
Prochlorperazine—Rash—Vandetanib—thyroid cancer	0.00139	0.0033	CcSEcCtD
Prochlorperazine—Dermatitis—Vandetanib—thyroid cancer	0.00139	0.0033	CcSEcCtD
Prochlorperazine—Headache—Vandetanib—thyroid cancer	0.00138	0.00328	CcSEcCtD
Prochlorperazine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00134	0.00318	CcSEcCtD
Prochlorperazine—Dyspnoea—Sorafenib—thyroid cancer	0.00133	0.00315	CcSEcCtD
Prochlorperazine—Coma—Doxorubicin—thyroid cancer	0.0013	0.00309	CcSEcCtD
Prochlorperazine—Photosensitivity—Epirubicin—thyroid cancer	0.00127	0.00302	CcSEcCtD
Prochlorperazine—Constipation—Sorafenib—thyroid cancer	0.00127	0.00302	CcSEcCtD
Prochlorperazine—Eczema—Epirubicin—thyroid cancer	0.00125	0.00295	CcSEcCtD
Prochlorperazine—Increased appetite—Epirubicin—thyroid cancer	0.00119	0.00283	CcSEcCtD
Prochlorperazine—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00119	0.00281	CcSEcCtD
Prochlorperazine—Urticaria—Sorafenib—thyroid cancer	0.00118	0.00281	CcSEcCtD
Prochlorperazine—Photosensitivity—Doxorubicin—thyroid cancer	0.00118	0.0028	CcSEcCtD
Prochlorperazine—Body temperature increased—Sorafenib—thyroid cancer	0.00118	0.00279	CcSEcCtD
Prochlorperazine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00116	0.00274	CcSEcCtD
Prochlorperazine—Eczema—Doxorubicin—thyroid cancer	0.00115	0.00273	CcSEcCtD
Prochlorperazine—Hypoglycaemia—Epirubicin—thyroid cancer	0.00115	0.00272	CcSEcCtD
Prochlorperazine—Increased appetite—Doxorubicin—thyroid cancer	0.0011	0.00262	CcSEcCtD
Prochlorperazine—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.0011	0.0026	CcSEcCtD
Prochlorperazine—Hypersensitivity—Sorafenib—thyroid cancer	0.0011	0.0026	CcSEcCtD
Prochlorperazine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00107	0.00254	CcSEcCtD
Prochlorperazine—Cardiac arrest—Epirubicin—thyroid cancer	0.00106	0.00252	CcSEcCtD
Prochlorperazine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00106	0.00252	CcSEcCtD
Prochlorperazine—Pruritus—Sorafenib—thyroid cancer	0.00105	0.0025	CcSEcCtD
Prochlorperazine—Cardiac arrest—Doxorubicin—thyroid cancer	0.000985	0.00234	CcSEcCtD
Prochlorperazine—Dizziness—Sorafenib—thyroid cancer	0.000984	0.00234	CcSEcCtD
Prochlorperazine—Asthma—Epirubicin—thyroid cancer	0.000967	0.00229	CcSEcCtD
Prochlorperazine—Influenza—Epirubicin—thyroid cancer	0.000967	0.00229	CcSEcCtD
Prochlorperazine—Dysphagia—Epirubicin—thyroid cancer	0.000967	0.00229	CcSEcCtD
Prochlorperazine—Eosinophilia—Epirubicin—thyroid cancer	0.000958	0.00227	CcSEcCtD
Prochlorperazine—Rash—Sorafenib—thyroid cancer	0.000938	0.00223	CcSEcCtD
Prochlorperazine—Dermatitis—Sorafenib—thyroid cancer	0.000938	0.00222	CcSEcCtD
Prochlorperazine—Headache—Sorafenib—thyroid cancer	0.000932	0.00221	CcSEcCtD
Prochlorperazine—Pancytopenia—Epirubicin—thyroid cancer	0.000919	0.00218	CcSEcCtD
Prochlorperazine—Asthma—Doxorubicin—thyroid cancer	0.000895	0.00212	CcSEcCtD
Prochlorperazine—Dysphagia—Doxorubicin—thyroid cancer	0.000895	0.00212	CcSEcCtD
Prochlorperazine—Influenza—Doxorubicin—thyroid cancer	0.000895	0.00212	CcSEcCtD
Prochlorperazine—Eosinophilia—Doxorubicin—thyroid cancer	0.000886	0.0021	CcSEcCtD
Prochlorperazine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000883	0.00209	CcSEcCtD
Prochlorperazine—Weight increased—Epirubicin—thyroid cancer	0.00088	0.00209	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000873	0.00207	CcSEcCtD
Prochlorperazine—Drowsiness—Epirubicin—thyroid cancer	0.000862	0.00205	CcSEcCtD
Prochlorperazine—Pancytopenia—Doxorubicin—thyroid cancer	0.00085	0.00202	CcSEcCtD
Prochlorperazine—Jaundice—Epirubicin—thyroid cancer	0.000841	0.00199	CcSEcCtD
Prochlorperazine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000817	0.00194	CcSEcCtD
Prochlorperazine—Weight increased—Doxorubicin—thyroid cancer	0.000815	0.00193	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000807	0.00192	CcSEcCtD
Prochlorperazine—Agranulocytosis—Epirubicin—thyroid cancer	0.000805	0.00191	CcSEcCtD
Prochlorperazine—Drowsiness—Doxorubicin—thyroid cancer	0.000798	0.00189	CcSEcCtD
Prochlorperazine—Jaundice—Doxorubicin—thyroid cancer	0.000778	0.00185	CcSEcCtD
Prochlorperazine—Oedema peripheral—Epirubicin—thyroid cancer	0.000763	0.00181	CcSEcCtD
Prochlorperazine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000745	0.00177	CcSEcCtD
Prochlorperazine—Erythema multiforme—Epirubicin—thyroid cancer	0.000732	0.00174	CcSEcCtD
Prochlorperazine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000706	0.00167	CcSEcCtD
Prochlorperazine—Arrhythmia—Epirubicin—thyroid cancer	0.000692	0.00164	CcSEcCtD
Prochlorperazine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000677	0.00161	CcSEcCtD
Prochlorperazine—Erythema—Epirubicin—thyroid cancer	0.000674	0.0016	CcSEcCtD
Prochlorperazine—Nervousness—Epirubicin—thyroid cancer	0.000655	0.00155	CcSEcCtD
Prochlorperazine—Muscle spasms—Epirubicin—thyroid cancer	0.000648	0.00154	CcSEcCtD
Prochlorperazine—Arrhythmia—Doxorubicin—thyroid cancer	0.00064	0.00152	CcSEcCtD
Prochlorperazine—Vision blurred—Epirubicin—thyroid cancer	0.000635	0.00151	CcSEcCtD
Prochlorperazine—Erythema—Doxorubicin—thyroid cancer	0.000624	0.00148	CcSEcCtD
Prochlorperazine—Agitation—Epirubicin—thyroid cancer	0.000619	0.00147	CcSEcCtD
Prochlorperazine—Nervousness—Doxorubicin—thyroid cancer	0.000606	0.00144	CcSEcCtD
Prochlorperazine—Leukopenia—Epirubicin—thyroid cancer	0.000603	0.00143	CcSEcCtD
Prochlorperazine—Muscle spasms—Doxorubicin—thyroid cancer	0.0006	0.00142	CcSEcCtD
Prochlorperazine—Cough—Epirubicin—thyroid cancer	0.000588	0.0014	CcSEcCtD
Prochlorperazine—Vision blurred—Doxorubicin—thyroid cancer	0.000588	0.00139	CcSEcCtD
Prochlorperazine—Convulsion—Epirubicin—thyroid cancer	0.000584	0.00139	CcSEcCtD
Prochlorperazine—Agitation—Doxorubicin—thyroid cancer	0.000573	0.00136	CcSEcCtD
Prochlorperazine—Dry mouth—Epirubicin—thyroid cancer	0.000561	0.00133	CcSEcCtD
Prochlorperazine—Leukopenia—Doxorubicin—thyroid cancer	0.000558	0.00132	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00055	0.00131	CcSEcCtD
Prochlorperazine—Oedema—Epirubicin—thyroid cancer	0.00055	0.00131	CcSEcCtD
Prochlorperazine—Infection—Epirubicin—thyroid cancer	0.000546	0.0013	CcSEcCtD
Prochlorperazine—Cough—Doxorubicin—thyroid cancer	0.000544	0.00129	CcSEcCtD
Prochlorperazine—Convulsion—Doxorubicin—thyroid cancer	0.00054	0.00128	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000539	0.00128	CcSEcCtD
Prochlorperazine—Skin disorder—Epirubicin—thyroid cancer	0.000534	0.00127	CcSEcCtD
Prochlorperazine—Dry mouth—Doxorubicin—thyroid cancer	0.000519	0.00123	CcSEcCtD
Prochlorperazine—Hypotension—Epirubicin—thyroid cancer	0.000514	0.00122	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000509	0.00121	CcSEcCtD
Prochlorperazine—Oedema—Doxorubicin—thyroid cancer	0.000509	0.00121	CcSEcCtD
Prochlorperazine—Infection—Doxorubicin—thyroid cancer	0.000506	0.0012	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000498	0.00118	CcSEcCtD
Prochlorperazine—Insomnia—Epirubicin—thyroid cancer	0.000498	0.00118	CcSEcCtD
Prochlorperazine—Skin disorder—Doxorubicin—thyroid cancer	0.000494	0.00117	CcSEcCtD
Prochlorperazine—Dyspnoea—Epirubicin—thyroid cancer	0.00049	0.00116	CcSEcCtD
Prochlorperazine—Somnolence—Epirubicin—thyroid cancer	0.000489	0.00116	CcSEcCtD
Prochlorperazine—Hypotension—Doxorubicin—thyroid cancer	0.000476	0.00113	CcSEcCtD
Prochlorperazine—Constipation—Epirubicin—thyroid cancer	0.00047	0.00112	CcSEcCtD
Prochlorperazine—Insomnia—Doxorubicin—thyroid cancer	0.00046	0.00109	CcSEcCtD
Prochlorperazine—Dyspnoea—Doxorubicin—thyroid cancer	0.000454	0.00108	CcSEcCtD
Prochlorperazine—Somnolence—Doxorubicin—thyroid cancer	0.000452	0.00107	CcSEcCtD
Prochlorperazine—Urticaria—Epirubicin—thyroid cancer	0.000437	0.00104	CcSEcCtD
Prochlorperazine—Constipation—Doxorubicin—thyroid cancer	0.000435	0.00103	CcSEcCtD
Prochlorperazine—Body temperature increased—Epirubicin—thyroid cancer	0.000435	0.00103	CcSEcCtD
Prochlorperazine—Hypersensitivity—Epirubicin—thyroid cancer	0.000405	0.000962	CcSEcCtD
Prochlorperazine—Urticaria—Doxorubicin—thyroid cancer	0.000404	0.000959	CcSEcCtD
Prochlorperazine—Body temperature increased—Doxorubicin—thyroid cancer	0.000402	0.000955	CcSEcCtD
Prochlorperazine—Pruritus—Epirubicin—thyroid cancer	0.000389	0.000923	CcSEcCtD
Prochlorperazine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000375	0.00089	CcSEcCtD
Prochlorperazine—Dizziness—Epirubicin—thyroid cancer	0.000364	0.000863	CcSEcCtD
Prochlorperazine—Pruritus—Doxorubicin—thyroid cancer	0.00036	0.000854	CcSEcCtD
Prochlorperazine—Rash—Epirubicin—thyroid cancer	0.000347	0.000823	CcSEcCtD
Prochlorperazine—Dermatitis—Epirubicin—thyroid cancer	0.000347	0.000822	CcSEcCtD
Prochlorperazine—Headache—Epirubicin—thyroid cancer	0.000345	0.000818	CcSEcCtD
Prochlorperazine—Dizziness—Doxorubicin—thyroid cancer	0.000337	0.000799	CcSEcCtD
Prochlorperazine—Rash—Doxorubicin—thyroid cancer	0.000321	0.000761	CcSEcCtD
Prochlorperazine—Dermatitis—Doxorubicin—thyroid cancer	0.000321	0.000761	CcSEcCtD
Prochlorperazine—Headache—Doxorubicin—thyroid cancer	0.000319	0.000756	CcSEcCtD
